【摘要】 目的：探讨阿利西尤单抗联合伊伐布雷定对STEMI患者PCI术后的应用效果。方法：选取在2023年10月至2024年10月佳木斯市中心医院收治入院并行PCI治疗的90例STEMI患者展开回顾性分析，根据入院早期是否应用阿利西尤单抗情况进行分组，将采取阿利西尤单抗联合伊伐布雷定治疗的45例患者分为试验组，将采取伊伐布雷定治疗的45例患者分为对照组。比较2组血脂代谢指标[低密度脂蛋白胆固醇（LDL-C）、甘油三酯、总胆固醇]，炎症因子[白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)、超敏C反应蛋白（Hs-CRP）]，心室重构[左心室质量指数（LVMI）、舒张末期室间隔厚度（LVST）]及颈动脉斑块[斑块积分、斑块面积、颈动脉内膜中层厚度（IMT）]，并对患者进行电话及门诊复查随访，记录其心血管不良事件（MACE）发生率。结果：治疗后，2组血脂代谢水平均低于治疗前，试验组较对照组低（P<0.05）；治疗后，2组炎症因子水平均低于治疗前，试验组较对照组低（P<0.05）；治疗后，经t检验，2组LVMI、LVST、斑块积分、斑块面积、TMT水平均低于治疗前，试验组低于对照组（P<0.05）；对所有患者进行术后6个月随访，通过随访发现，试验组MACE总发生率为8.89%，对照组为26.67%，经x~2检验发现，试验组MACE总发生率低于对照组（P<0.05）。结论：STEMI患者PCI术后采取阿利西尤单抗联合伊伐布雷定治疗可进一步改善患者血脂代谢水平，降低机体炎症反应，逆转部分颈动脉斑块，改善心室重构，从而可进一步降低患者远期心血管不良事件发生风险。更多还原

【Abstract】 Objective: To investigate the application effect of aleximumab combined with ivabradine in patients with STEMI after PCI. Methods: A retrospective analysis was conducted on 90 STEMI patients admitted to Jiamusi Central Hospital for PCI treatment from October 2023 to October 2024. The patients were divided into two groups based on whether they were treated with aleximumab in the early stages of admission. The 45 patients treated with aleximumab combined with ivabradine were assigned to the experimental group, and the 45 patients treated with ivabradine were assigned to the matched group. Compare two groups of blood lipid metabolism indicators [Low density lipoprotein cholesterol(LDL-C), triglycerides, total cholesterol], inflammatory factors [interleukin-6(IL-6),matrix metalloproteinase-9(MMP-9), hypersensitive C-reactive protein(Hs CRP)], ventricular remodeling [Left ventricular mass index(LVMI), end diastolic interventricular thickness(LVST)], and carotid plaques [plaque score,plaque area, carotid intima-media thickness(CarST)]. otid intima-media thickness(IMT) was observed, and patients were followed up by telephone and outpatient follow-up for 6 months to record the incidence of cardiovascular adverse events(MACE). Results: Post-treatment, the level of lipid metabolism in both groups was lower than that pretherapy, and the level of lipid metabolism in the test group was lower than that in the matched group(P<0.05);Post-treatment, the levels of inflammatory factors in both groups were lower than that pretherapy, and the test group was lower than that in the matched group(P<0.05); Post-treatment, t-test showed that LVMI LVST, The plaque score, plaque area, and TMT level were all lower than pretherapy, and the experimental group was lower than the matched group(P<0.05); All patients were followed up for 6 months after surgery. Through follow-up, it was found that the total incidence of MACE in the experimental group was 8.89%, while that in the matched group was26.67%. According to the chi square test, the total incidence of MACE in the experimental group was lower than that in the matched group(P<0.05). Conclusion: The combination of aleximumab and ivabradine treatment after PCI in STEMI patients can further improve the patient’s lipid metabolism, reduce the body’s inflammatory response, reverse some carotid plaques, improve ventricular remodeling, and thus further reduce the risk of long-term cardiovascular adverse events in patients.更多还原